211 related articles for article (PubMed ID: 21993412)
21. Amyloid beta peptide-activated signal pathways in human platelets.
Shen MY; Hsiao G; Fong TH; Chen HM; Chou DS; Lin CH; Sheu JR; Hsu CY
Eur J Pharmacol; 2008 Jul; 588(2-3):259-66. PubMed ID: 18511035
[TBL] [Abstract][Full Text] [Related]
22. P2X1-initiated p38 signalling enhances thromboxane A2-induced platelet secretion and aggregation.
Huang Z; Liu P; Zhu L; Li N; Hu H
Thromb Haemost; 2014 Jul; 112(1):142-50. PubMed ID: 24633352
[TBL] [Abstract][Full Text] [Related]
23. Potent antiplatelet activity of sesamol in an in vitro and in vivo model: pivotal roles of cyclic AMP and p38 mitogen-activated protein kinase.
Chang CC; Lu WJ; Chiang CW; Jayakumar T; Ong ET; Hsiao G; Fong TH; Chou DS; Sheu JR
J Nutr Biochem; 2010 Dec; 21(12):1214-21. PubMed ID: 20015631
[TBL] [Abstract][Full Text] [Related]
24. Levobupivacaine differentially suppresses platelet aggregation by modulating calcium release in a dose-dependent manner.
Liou JT; Mao CC; Liu FC; Lin HT; Hung LM; Liao CH; Day YJ
Acta Anaesthesiol Taiwan; 2012 Sep; 50(3):112-21. PubMed ID: 23026170
[TBL] [Abstract][Full Text] [Related]
25. 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets.
Wu CC; Wang TW; Wang WY; Hsieh PW; Wu YC
Eur J Pharmacol; 2005 Dec; 527(1-3):37-43. PubMed ID: 16313903
[TBL] [Abstract][Full Text] [Related]
26. Antiplatelet activity of hesperetin, a bioflavonoid, is mainly mediated by inhibition of PLC-gamma2 phosphorylation and cyclooxygenase-1 activity.
Jin YR; Han XH; Zhang YH; Lee JJ; Lim Y; Chung JH; Yun YP
Atherosclerosis; 2007 Sep; 194(1):144-52. PubMed ID: 17092506
[TBL] [Abstract][Full Text] [Related]
27. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets.
Horie S; Yamada M; Satoh M; Noritake S; Hiraishi S; Kizaki K; Kurusu O; Nakahara T; Ishii H; Kazama M
Biol Pharm Bull; 1997 Jun; 20(6):625-31. PubMed ID: 9212979
[TBL] [Abstract][Full Text] [Related]
28. Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production.
Jeng JH; Wu HL; Lin BR; Lan WH; Chang HH; Ho YS; Lee PH; Wang YJ; Wang JS; Chen YJ; Chang MC
Atherosclerosis; 2007 Apr; 191(2):250-8. PubMed ID: 16797553
[TBL] [Abstract][Full Text] [Related]
29. SIN-1, the main metabolite of molsidomine, inhibits prostaglandin endoperoxide analogue- and arachidonic acid-induced platelet aggregation as well as platelet thromboxane A2 formation.
Block HU; Förster W; Heinroth I
Arzneimittelforschung; 1982; 32(3):189-94. PubMed ID: 6896278
[TBL] [Abstract][Full Text] [Related]
30. Antiplatelet effect of green tea catechins: a possible mechanism through arachidonic acid pathway.
Son DJ; Cho MR; Jin YR; Kim SY; Park YH; Lee SH; Akiba S; Sato T; Yun YP
Prostaglandins Leukot Essent Fatty Acids; 2004 Jul; 71(1):25-31. PubMed ID: 15172681
[TBL] [Abstract][Full Text] [Related]
31. Role of the Pyk2-MAP kinase-cPLA2 signaling pathway in shear-dependent platelet aggregation.
Sun L; Feng S; Reséndiz JC; Lu X; Durante W; Kroll MH
Ann Biomed Eng; 2004 Sep; 32(9):1193-201. PubMed ID: 15493507
[TBL] [Abstract][Full Text] [Related]
32. Reduction of platelet cytosolic phospholipase A2 activity by atorvastatin and simvastatin: biochemical regulatory mechanisms.
Moscardó A; Vallés J; Latorre A; Madrid I; Santos MT
Thromb Res; 2013 Apr; 131(4):e154-9. PubMed ID: 23352311
[TBL] [Abstract][Full Text] [Related]
33. The mechanism of anti-platelet activity of davallialactone: involvement of intracellular calcium ions, extracellular signal-regulated kinase 2 and p38 mitogen-activated protein kinase.
Kim SD; Lee IK; Lee WM; Cho JY; Park HJ; Oh JW; Park SC; Kim SK; Kwak YS; Yun BS; Rhee MH
Eur J Pharmacol; 2008 Apr; 584(2-3):361-7. PubMed ID: 18313047
[TBL] [Abstract][Full Text] [Related]
34. Lipopolysaccharide as trigger of platelet aggregation via eicosanoid over-production.
Nocella C; Carnevale R; Bartimoccia S; Novo M; Cangemi R; Pastori D; Calvieri C; Pignatelli P; Violi F
Thromb Haemost; 2017 Jul; 117(8):1558-1570. PubMed ID: 28492699
[TBL] [Abstract][Full Text] [Related]
35. Inhibitory effect of allyl isothiocyanate on platelet aggregation.
Lee DS; Kim TH; Jung YS
J Agric Food Chem; 2014 Jul; 62(29):7131-9. PubMed ID: 24980285
[TBL] [Abstract][Full Text] [Related]
36. Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect.
Remuzzi G; Benigni A; Dodesini P; Schieppati A; Livio M; De Gaetano G; Day SS; Smith WL; Pinca E; Patrignani P; Patrono C
J Clin Invest; 1983 Mar; 71(3):762-8. PubMed ID: 6298281
[TBL] [Abstract][Full Text] [Related]
37. Functional role of NADPH oxidase in activation of platelets.
Chlopicki S; Olszanecki R; Janiszewski M; Laurindo FR; Panz T; Miedzobrodzki J
Antioxid Redox Signal; 2004 Aug; 6(4):691-8. PubMed ID: 15242549
[TBL] [Abstract][Full Text] [Related]
38. Induction of central signalling pathways and select functional effects in human platelets by beta-boswellic acid.
Poeckel D; Tausch L; Altmann A; Feisst C; Klinkhardt U; Graff J; Harder S; Werz O
Br J Pharmacol; 2005 Oct; 146(4):514-24. PubMed ID: 16086030
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological characterization of 2NTX-99 [4-methoxy-N1-(4-trans-nitrooxycyclohexyl)-N3-(3-pyridinylmethyl)-1,3-benzenedicarboxamide], a potential antiatherothrombotic agent with antithromboxane and nitric oxide donor activity in platelet and vascular preparations.
Buccellati C; Sala A; Rossoni G; Capra V; Rovati GE; Di Gennaro A; Folco G; Colli S; Casagrande C
J Pharmacol Exp Ther; 2006 May; 317(2):830-7. PubMed ID: 16399881
[TBL] [Abstract][Full Text] [Related]
40. Differential Roles of the NADPH-Oxidase 1 and 2 in Platelet Activation and Thrombosis.
Delaney MK; Kim K; Estevez B; Xu Z; Stojanovic-Terpo A; Shen B; Ushio-Fukai M; Cho J; Du X
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):846-54. PubMed ID: 26988594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
